Early in the decade the company had been dogged by R&D failures, most notably of Vanlev, a high -
profile hypertension drug that had been hailed as a can't - miss blockbuster but then fell short of even getting FDA approval.
Regorafenib had a similar safety and side effect
profile to sorafenib, with
hypertension, hand - foot skin reaction, fatigue and diarrhea all being significantly more common in patients taking the
drug.